Skip to main content
Premium Trial:

Request an Annual Quote

Varian Acquires FTMS Firm IonSpec for $16M in Cash

NEW YORK, Feb. 27 (GenomeWeb News) - Varian said today that it has acquired IonSpec, picking up the company's Fourier transform mass spectrometry technology.

 

Varian said that it paid $16 million in cash, including the paydown of assumed debt, for IonSpec. Additional payments could be made if products based on the FTMS technology reach specific financial targets over a three-year period.

Additional terms of the transaction were not disclosed.

 

Varian noted that the deal is part of its strategy to strengthen its detection product portfolio, which includes nuclear magnetic resonance and magnetic resonance imaging, mass spectrometry, and Fourier transform-infrared systems.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.